IN-DATE
5959480: BD Bard Sepramesh IP Composite Polypropylene Mesh for Hernia Repair 4" x 8"
Sign in to add this product to your favorites!
| Price: | $449.00 per box of 1 |
|---|---|
| In Stock: | 0 box of 1 |
| Expiration: | In-Date |
We currently do not have this item in stock, but we can email you as soon as it is available.
Additional Details
BD Bard Sepramesh™ IP Composite Polypropylene Mesh
Sepramesh™ IP Composite is a polypropylene mesh with a hydrogel safety coating, which resorbs within 30 days providing visceral protection during the critical healing period.
The uncoated monofilament parietal side of Sepramesh™ IP Composite stimulates a fast fibrotic response. This results in strong tissue incorporation into the abdominal wall, which provides a strong long-term repair, minimizing recurrences and the need for permanent transfixation sutures.
AccessGUDID Info
- FDA Product Code: FTL
- FDA Product Code Name: Mesh, surgical, polymeric
- GMDN Term Code: 44756
- GMDN Term Name: Extra-gynaecological surgical mesh, composite-polymer
- GMDN Term Description: A partially-bioabsorbable, implantable material (e.g., flat sheet) made of two or more polymers that includes a bioabsorbable polymer [e.g., polyglycolic acid (PGA)] and a non-bioabsorbable polymer [e.g., polyethylene (PE)] intended for extra-gynaecological, non-dental tissue repair/reinforcement application(s) [e.g., pericardial reinforcement, plastic surgery, abdominal hernia repair]. It may also be intended as a short-term scaffold for tissue regeneration. Disposable devices associated with implantation may be supplied with the mesh.
Manufacturer
C.R. Bard (a part of BD - Becton, Dickinson and Company) was a global leader in the development and manufacturing of innovative medical technologies. Known for their high-quality products, Bard specialized in solutions for vascular access, urology, oncology, and surgical specialties. Their product portfolio included catheters, biopsy devices, implantable ports, and hernia repair systems, designed to enhance patient care and procedural efficiency. As part of BD, the legacy of C.R. Bard continues to drive advancements in healthcare, delivering trusted solutions that improve outcomes for patients and providers worldwide.
